| Name | Title | Contact Details |
|---|
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biocheck is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helping protect life through fundamental breakthroughs in vaccine adjuvant design and manufacturing.
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.